Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

May 2017

»
S
M
T
W
T
F
S
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·

Projects

A Blueprint for Success: Understanding the...

We are using a combination of statistical analysis and transmission modeling, in collaboration with the NYC Dept of Health &...

Read More

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

TB Modeling and Analysis Consortium

The TB MAC brings TB modelers together from a wide range of institutions to answer questions of global policy relevance.  I...

Read More

FlexDx-TB: A flexible, user-friendly model of...

We have developed a web-based model that allows decision-makers to input local epidemiological and economic values and receive...

Read More